Temporomandibular Disorders (TMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Temporomandibular Disorders (TMD) Market Outlook

Thelansis’s “Temporomandibular Disorders (TMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Temporomandibular Disorders treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Temporomandibular Disorders (TMD) Overview

Temporomandibular disorder (TMD) encompasses conditions affecting the orofacial region, specifically the masticatory muscles and temporomandibular joint (TMJ). TMD is characterized by pain in the TMJ, restricted mandibular movement, and TMJ sounds. The etiology of TMD is not fully understood, but it is believed to involve multiple factors. Myofascial and intraarticular TMDs differ in their underlying causes. Myofascial TMD is characterized by tension, fatigue, and pain in the masticatory muscles. Various factors contribute to muscular dysfunction, including stress, parafunctional habits like bruxism, abnormal posture, and psychological conditions Chronic pain conditions such as fibromyalgia are also commonly associated with TMD. Intraarticular TMD refers to inflammatory or mechanical factors affecting the TMJ, with articular disc displacement being the most prevalent. Common signs and symptoms of TMD include jaw discomfort or soreness, headaches, pain in the face, neck, shoulder, or back, earaches or tinnitus unrelated to inner ear infections, and teeth clenching. The National Institute of Dental and Craniofacial Research classifies TMD into myofascial pain, internal derangement of the joint, and degenerative joint disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line pharmacological treatment for both acute and chronic forms of TMD. Benzodiazepines may be prescribed for recurrent masticatory muscle spasms and bruxism when relaxation techniques have failed. Tricyclic antidepressants can be considered for symptom improvement based on their effectiveness in other pain disorders.

• TMD is the second most prevalent musculoskeletal pain condition, with low back pain being the most common. Worldwide, the prevalence of TMD pain in children ranges from 0.2% to 28%, while the occurrence of TMJ pain varies from 0.7% to 4%, depending on age. Among adults, the estimated prevalence ranges from 2% to 8% for males and 4% to 15% for females.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: